Organic revenue grew 15.9% year-over-year, but a $144.2 million goodwill write-down led to a net loss and lower Adjusted EBITDA. Guidance for 2026 was revised downward due to discontinued operations and margin pressures, while the Diabetes Health business sale refocuses on core segments.Original do…
Organic revenue grew 15.9% year-over-year, but a $144.2 million goodwill write-down led to a net loss and lower Adjusted EBITDA. Guidance for 2026 was revised downward due to discontinued operations and margin pressures, while the Diabetes Health business sale refocuses on core segments.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
